ArticlePloS one2018

Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.

Hong Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.